Verrica Pharmaceuticals Inc. (VRCA) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.21 (-4.18% 1D, market cap $55.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, VRCA ranks #727 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRCA carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CTOR (Citius Oncology Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $55.2M) and RNTX (Rein Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $54.8M). Among the 5-stock peer group, VRCA leads on earnings multiple (N/A) while VRCA leads on capital efficiency (-35.0% ROIC).
Per VRCA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001660334), Verrica Pharmaceuticals Inc. generated $35.6M in revenue (+370.2% YoY), -$17.9M in net income, and -$17.6M in free cash flow against $47.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 31.3 (OVERSOLD (<32))
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While VRCA currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.34) and Max Pain ($3.37) forces dealer call-delta covering toward $10.31.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Verrica Pharmaceuticals Inc. (VRCA) dropped -4.18% to $3.21, trading at 2% of its 52-week range ($3.21 – $9.82). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Verrica Pharmaceuticals Inc. (VRCA) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Verrica Pharmaceuticals Inc. (VRCA) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Verrica Pharmaceuticals Inc. (VRCA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Verrica Pharmaceuticals Inc. (VRCA) market action, institutional positioning, and fundamental catalysts.
MyChesCo report covering Verrica Pharmaceuticals Inc. (VRCA) market action, institutional positioning, and fundamental catalysts.
Investing.com India report covering Verrica Pharmaceuticals Inc. (VRCA) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Verrica Pharmaceuticals Inc. (VRCA) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Verrica Pharmaceuticals Inc. (VRCA) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +370.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on VRCA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for VRCA. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Verrica Pharmaceuticals Inc. (VRCA) ranks #727 by composite RQD confidence (32/100, grade E) and #726 by equity capitalization ($55.1M). Within this direct 5-issuer industry benchmark cohort, VRCA leads on earnings valuation at N/A trailing P/E, while VRCA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RNTX currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with VRCA at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VRCA
ACTIVE
Verrica Pharmaceuticals Inc. | E | 32/100 | — | — | -35.0% | -4.18% | $55.1M | Benchmark Subject |
| CTOR Citius Oncology Inc. | E | 34/100 | — | — | -35.0% | +7.24% | $55.2M | /ctor-vs-vrca → |
| RNTX Rein Therapeutics Inc. | D- | 38/100 | — | — | -35.0% | -5.16% | $54.8M | /rntx-vs-vrca → |
| NMAD Nomad Power Solutions Inc. | E | 31/100 | — | — | -35.0% | -2.53% | $55.9M | /nmad-vs-vrca → |
| HRTX Heron Therapeutics Inc. | E | 34/100 | — | 73.3% | -35.0% | +6.27% | $56.0M | /hrtx-vs-vrca → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Verrica Pharmaceuticals Inc. (VRCA) reported GAAP revenue of $35.6M (+370.2% vs. FY2024 revenue of $7.6M , and +594.3% cumulative change since FY2023) , GAAP net income of -$17.9M, operating cash flow of -$17.6M, and free cash flow of -$17.6M (+71.1% YoY). On the balance sheet, VRCA closed FY2025 with $47.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $35.6M | -$17.9M | -$17.6M | -$17.6M | $47.1M | — |
| FY2024 (FY) | 2024-12-31 | $7.6M | -$76.6M | -$60.9M | -$61.0M | $54.1M | — |
| FY2023 (FY) | 2023-12-31 | $5.1M | -$67.0M | -$38.6M | -$38.6M | — | — |
As of 2026-11-03, Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.21 (-4.18% 1D, market cap $55.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, VRCA ranks #727 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRCA carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CTOR (Citius Oncology Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $55.2M) and RNTX (Rein Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $54.8M). Among the 5-stock peer group, VRCA leads on earnings multiple (N/A) while VRCA leads on capital efficiency (-35.0% ROIC).
Per VRCA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001660334), Verrica Pharmaceuticals Inc. generated $35.6M in revenue (+370.2% YoY), -$17.9M in net income, and -$17.6M in free cash flow against $47.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
VRCA last traded at $3.21 (-4.18% on volume of 55,797 shares), positioning the stock -26.04% below its 50-day simple moving average ($4.34) and -42.37% below its 200-day simple moving average ($5.57). Across its 52-week range of $3.21 to $9.82, VRCA sits at the 0.0% percentile with a 14-day RSI of 31.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.81 to $3.61).
Verrica Pharmaceuticals Inc. (VRCA) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.21 (-4.18% 1D, market capitalization $55.1M).
Verrica Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..1B. The company's products, customers, and revenue model are not described in detail.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Verrica Pharmaceuticals Inc. (VRCA) reported $35.6M in annual revenue (up from $7.6M in FY2024, +370.2% YoY) and -$17.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($5.1M revenue, -$67.0M net income) through FY2025, VRCA scaled operating cash flow to -$17.6M and free cash flow to -$17.6M, backed by $47.1M in total assets against $0 in total debt.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), VRCA carries a macro regime beta of 1.00 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for Verrica Pharmaceuticals Inc. (VRCA) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Verrica Pharmaceuticals Inc. (VRCA) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Verrica Pharmaceuticals Inc. (VRCA) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Verrica Pharmaceuticals Inc. (VRCA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Verrica Pharmaceuticals Inc. (VRCA) market action, institutional positioning, and fundamental catalysts.
MyChesCo report covering Verrica Pharmaceuticals Inc. (VRCA) market action, institutional positioning, and fundamental catalysts.
Investing.com India report covering Verrica Pharmaceuticals Inc. (VRCA) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Verrica Pharmaceuticals Inc. (VRCA) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Verrica Pharmaceuticals Inc. (VRCA) market action, institutional positioning, and fundamental catalysts.
Picked up a starter position in VRCA in my $100K Virtual Cash book at $3.35. Revenue grew from $5.1M in FY 2023 to $35.6M in FY 2025 while the net loss narrowed to -$17.9M, and the news feed reports unlocked non-dilutive credit facility funding.. Trading inside a $3.25–$9.82 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
Here is the bear case nobody on the bull side wants to address on VRCA: ROIC of -35%, a 0% FCF yield, and a Roarable Sell verdict with a 44 RQD score indicate weak cash generation and negative distribution signals.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: